abstract |
A P-selectin glycoprotein ligand 1 (PSGL-1) antagonist for use in eliciting a T cell response or restoring T cell function in a method of treating an infectious disease or cancer , said method comprising administering the P-selectin glycoprotein ligand 1 (PSGL-1) antagonist to a subject in need thereof, wherein the response of CD4+-dependent CD8+ T lymphocytes is increased. |